Lorlatinib: all 46 studies that test it
Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNot yet recruitingNCT07750704Phase 2
- AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerRecruitingNCT07617337Phase 1
- Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerRecruitingNCT07415005Phase 2
- Lorlatinib in ROS1+ NSCLC With Brain MetastasisNot yet recruitingNCT07083687Phase 2
- Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial TranscriptomicsNot yet recruitingNCT06893354Phase 4
- Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung AdenocarcinomaNot yet recruitingNCT06858410Phase 3
- Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNot yet recruitingNCT06682884Phase 2
- Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextRecruitingNCT06487078Not applicable
- A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibRecruitingNCT06378892Phase 2
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionRecruitingNCT06333899Early Phase 1
- Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCRecruitingNCT06092086Phase 2
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingNCT03126916Phase 3
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in IndiaCompletedNCT04541706Phase 4Results posted
- Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerCompletedNCT04362072Phase 4Results posted
- A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaCompletedNCT03909971Phase 2Results posted
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
- Hepatic Impairment Study for Lorlatinib in Cancer PatientsTerminatedNCT03726333Phase 1Results posted
- Lorlatinib Renal Impairment StudyCompletedNCT03542305Phase 1Results posted
- NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)CompletedNCT03107988Phase 1Results posted
- A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCActive, not recruitingNCT03052608Phase 3Results posted
- A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy VolunteersCompletedNCT02804399Phase 1Results posted
- Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)TerminatedNCT02584634Phase 1/2Results posted
- A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular AlterationsCompletedNCT01970865Phase 1/2Results posted
- Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesActive, not recruitingNCT06282874Phase 4
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerActive, not recruitingNCT06007937Phase 1/2
- Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
- Induction Lorlatinib in Stage III Non-small Cell Lung CancerActive, not recruitingNCT05740943Phase 2
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Phase 2
- A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver DysfunctionCompletedNCT05224609Phase 1
- Lorlatinib Continuation StudyActive, not recruitingNCT05144997Phase 4
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
- Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)Active, not recruitingNCT04621188Phase 2
- Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS DiseaseCompletedNCT04541407Phase 1
- Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC PatientsActive, not recruitingNCT04127110Phase 2
- Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerCompletedNCT04111705Phase 2
- Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy ParticipantsCompletedNCT03961997Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Study of Lorlatinib in ROS1 Rearranged NSCLCStatus unknownNCT03612154Phase 2
- A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive LymphomaCompletedNCT03505554Phase 2
- PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung CancerStatus unknownNCT03439215Phase 2
- Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male VolunteersCompletedNCT03184168Phase 1
- A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial LesionsStatus unknownNCT02927340Phase 2
- A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy VolunteersCompletedNCT02838264Phase 1
- PPI And Food Effect Study For PF-06463922 In Healthy VolunteersCompletedNCT02569554Phase 1
- A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male VolunteersCompletedNCT02564562Phase 1